Tositumomab I-131
- Generic Name
- Tositumomab I-131
- Drug Type
- Biotech
- CAS Number
- 192391-48-3
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
- Conditions
- Lymphoma, Small Cleaved-Cell, FollicularLymphoma, Large-Cell, FollicularLymphoma, FollicularLymphoma, Non-Hodgkin
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00319332
- Locations
- 🇺🇸
GSK Clinical Trials Call Center, Tacoma, Washington, United States
🇺🇸GSK Clinical Trial Call Center, Seattle, Washington, United States
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00135200
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-06-19
- Last Posted Date
- 2007-09-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00062894
- Locations
- 🇺🇸
University of Michigan Medical Center, Ann Arbor, Michigan, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Expanded Access Study of Iodine-131 Anti-B1 Antibody
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2001-08-20
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Corixa Corporation
- Registration Number
- NCT00022958
- Locations
- 🇺🇸
Central Recruiting Information, South San Francisco, California, United States
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2001-08-20
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Corixa Corporation
- Registration Number
- NCT00022932
- Locations
- 🇺🇸
Tufts New England Medical Center, Boston, Massachusetts, United States
🇺🇸Cornell Medical Center, New York, New York, United States
🇺🇸Rush Medical Center, Chicago, Illinois, United States
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- First Posted Date
- 2001-08-20
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Corixa Corporation
- Registration Number
- NCT00022945
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Rush-Presbyterian-St. Lukes Medical Center, Chicago, Illinois, United States
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2001-08-17
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Corixa Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT00022880
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Long Island Jewish Medical Center, New Hyde Park, New York, United States
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2001-08-17
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Corixa Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT00022906
- Locations
- 🇺🇸
Cornell Medical Center, New York, New York, United States
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2001-08-17
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Corixa Corporation
- Registration Number
- NCT00022893
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸University of Michigan Cancer & Geriatric Center, Ann Arbor, Michigan, United States
🇬🇧Christie Hospital NHS Trust, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.